DUBLIN, October 06, 2021--(BUSINESS WIRE)--The "Global Gene Delivery Technologies Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The global gene delivery technologies market size is expected to reach USD 7.9 billion by 2028. The market is expected to expand at a CAGR of 15.1% from 2021 to 2028.
Technological advancements in viral vectors, a growing pipeline of advanced therapies, and a rising number of regulatory approvals for advance therapy products are some key driving forces of the market.
Several novel tools are being introduced for genetic alterations that have facilitated the scientific community to delineate the disease intricacies at the genomic level, leading to the emergence of novel gene delivery approaches.
Furthermore, ongoing research to develop clinically relevant vectors including viral and non-viral vectors to combat chronic illnesses such as cancer, Alzheimer's, and others through advanced therapies is spurring the market revenue.
An increase in investment and financing in the space to support the research, development, and manufacturing of various modes of gene transfer further accelerates the revenue growth. Currently, around 70% of gene and cell therapy programs are based on viral vectors leading to organic revenue growth for biological delivery technologies. The operating players are investing significantly to scale up their viral vector manufacturing capability and meet the growing demand.
Considering growing opportunities in physio-chemical gene delivery approaches, key players are making focused efforts to boost their business presence.
For instance, nanoparticles have proven their efficiency as promising vehicles for clinical usage owing to their tunable morphology, and biological behaviors. Such ongoing developments in the space are anticipated to accelerate revenue growth in this market in the coming years.
Gene Delivery Technologies Market Report Highlights
The wide implementation of biological gene delivery technologies in clinical usage owing to their high efficiency and specificity has resulted in the segment's largest revenue share in 2020
Gene therapy development is the key revenue-generating application in the 2020 market owing to constantly expanding pipeline programs of therapies against life-threatening conditions coupled with the recent success of CAR-T therapies
The recent pandemic of SARS-CoV-2 has also resulted in substantial global investments in R&D of viral vector-based vaccine to combat the virus, resulting in lucrative growth of this segment
The ex vivo method accounted for the major revenue share owing to its advantages such as high transduction efficiency and less immunogenic responses
However, both in vivo and ex vivo have shown clinical success in the treatment of chronic conditions, thus both segments are expected to witness lucrative growth in the coming years
Given the high number of biotech companies and a favorable regulatory environment in the U.S.; North America dominated the global market in terms of revenue
On the other hand, Asia Pacific is projected to grow at the fastest pace during the forecast period
Constantly evolving CDMO and viral vector manufacturing landscapes through plant expansions and new sites being built across the Asian countries is spurring the adoption of vectors in this region
The key players are engaged in collaboration with therapy developers to support their product development process
Market driver analysis
Advances in gene and cell research and therapeutic delivery
Increase in funding by government and private players
Rising competition amongst market players
Market restraint analysis
High Cost of Gene Delivery Systems
Home brew reagents restricts sale of commercial products
Market opportunity analysis
Rising pressure on drug developers to meet consumer's therapeutics demand
Expanding market in regions such as APAC and LATAM
Market Challenge analysis
Technical challenges related to gene delivery techniques
F. Hoffmann - La Roche AG
Thermo Fisher Scientific, Inc.
Horizon Discovery Group Co.
OriGene Technologies, Inc.
Takara Bio Inc.
Bio - Rad Laboratories, Inc.
System Biosciences llc
Sirion - Biotech GmbH
For more information about this report visit https://www.researchandmarkets.com/r/3d8d3p
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005875/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900